These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34029578)

  • 1. Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.
    Smith MA; Burger EA; Castanon A; de Kok IMCM; Hanley SJB; Rebolj M; Hall MT; Jansen EEL; Killen J; O'Farrell X; Kim JJ; Canfell K
    Prev Med; 2021 Oct; 151():106623. PubMed ID: 34029578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination.
    Velentzis LS; Smith MA; Killen J; Brotherton JML; Guy R; Canfell K
    Elife; 2023 Oct; 12():. PubMed ID: 37831501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of COVID-19-related care disruptions on cervical cancer screening in the United States.
    Burger EA; Jansen EE; Killen J; Kok IM; Smith MA; Sy S; Dunnewind N; G Campos N; Haas JS; Kobrin S; Kamineni A; Canfell K; Kim JJ
    J Med Screen; 2021 Jun; 28(2):213-216. PubMed ID: 33730899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening.
    Poljak M; Cuschieri K; Waheed DE; Baay M; Vorsters A
    Acta Dermatovenerol Alp Pannonica Adriat; 2021 Mar; 30(1):21-26. PubMed ID: 33765753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities.
    Wentzensen N; Clarke MA; Perkins RB
    Prev Med; 2021 Oct; 151():106596. PubMed ID: 34217415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
    Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study.
    Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M;
    Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
    Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
    BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Canadian survey on the impact of the COVID-19 pandemic on cervical cancer screening and management: cross-sectional survey of healthcare professionals.
    El-Zein M; Ali R; Farah E; Botting-Provost S; Franco EL;
    Elife; 2023 Jun; 12():. PubMed ID: 37377399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low rates of HPV vaccination and cervical cancer screening: Challenges and opportunities in the context of the COVID-19 pandemic.
    Smith DL; Perkins RB
    Prev Med; 2022 Jun; 159():107070. PubMed ID: 35461955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses.
    Castanon A; Rebolj M; Pesola F; Sasieni P
    Br J Cancer; 2021 Apr; 124(8):1361-1365. PubMed ID: 33558708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions.
    Burger EA; de Kok IMCM; O'Mahony JF; Rebolj M; Jansen EEL; de Bondt DD; Killen J; Hanley SJ; Castanon A; Regan MC; Kim JJ; Canfell K; Smith MA
    Elife; 2022 Oct; 11():. PubMed ID: 36222673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV testing and vaccination in Europe.
    Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
    J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.